SPOTLIGHT: Meridian buys recombinant proteins


Meridian Bioscience has agreed to buy a line of infectious disease recombinant proteins from Vybion for an undisclosed sum of money. The pact covers future royalties on product sales. Release | Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.